Hepatorenal Tyrosinemia
Hepatorenal tyrosinemia, also known as type I tyrosinemia, is a genetic disorder characterized by a deficiency of fumarylacetoacetate hydrolase (FAH). This enzyme is vital for the breakdown of tyrosine, an amino acid found in various foods. As a result, individuals with this condition experience an accumulation of tyrosine and its by-products in their tissues and organs.
Typically, hepatorenal tyrosinemia manifests in infants within the first few months of life. If left untreated, it can lead to severe liver and kidney damage, potentially resulting in organ failure. To manage this condition, individuals must adhere to a specialized diet that is low in both tyrosine and phenylalanine, another amino acid. This dietary approach is combined with medication to alleviate symptoms and maintain overall health.
Tyrosinemia Types II & III
Tyrosinemia type II, also known as Richner Hahart syndrome, and type III are extremely uncommon variations of this condition. Type II is the result of a deficiency in the enzyme tyrosine aminotranserase (TAT), which leads to the development of skin lesions on the palms and soles, as well as corneal ulcers. On the other hand, type III is caused by a deficiency in the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). Both types may present with additional symptoms such as intellectual disability, seizures, and mild loss of coordination. Upon diagnosis, treatment typically involves medication management and adherence to a restricted diet.